Praxis Precision Medicines’ PRAX-628 shows high response in epilepsy study

Praxis Precision Medicines provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. PPR studies measure electroencephalogram – EEG – signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy. In the Phase 2a PPR study, five patients in the 15 mg cohort were evaluable, and three patients were evaluable in the 45 mg cohort. In the 45 mg cohort, 100% of patients achieved a complete response. In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response. Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures. Praxis plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024.